MAP Pharmaceuticals, Inc. (MAPP) Reports Q4 Loss of 45c/Share; to Restate Interim Statements for First 3 Qtrs. of 2011

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. DVLT
8. ADYYF
9. WDAY
10. ADYEN:NA

March 29, 2012 7:03 AM EDT
Get Alerts MAPP Hot Sheet
Price: $28.29 -0.04%

Financial Fact:
Interest income: 0

Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $837 thousand versus the consensus estimate of $2.74 million.

To restate interim statements for the first three quarters in 2011. Cites the accounting treatment of a $60 million upfront payment.

For earnings history and earnings-related data on MAP Pharmaceuticals, Inc. (MAPP) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings